Medication evidence and regulatory status

Aleniglipron Oral GLP-1 Research and FDA Status

Aleniglipron, formerly known as GSBR-1290, is an investigational oral small-molecule GLP-1 receptor agonist being studied for obesity and metabolic disease.

Approved medicationsAppointments

Reviewing aleniglipron oral GLP-1 research

Current FDA status: This medicine or topic includes investigational treatment. Retatrutide, CagriSema, MariTide and aleniglipron are not FDA-approved for routine prescribing as of September 4, 2026. W8MD does not offer products sold online as “research peptides.”

Trial stage

Clinical research includes dose-ranging and pivotal studies. Until regulatory review is completed, efficacy, approved population, final dose, warnings, labeling and commercial availability are not established.

ClinicalTrials.gov aleniglipron study

How W8MD can help now

Patients do not need to wait for a future drug to receive evidence-based care. W8MD can compare currently approved weight-loss medications, nutrition, sleep treatment and non-medication plans using medical history, prior attempts, preferences, coverage and sustainable cost.

Discuss currently available options with W8MD

Brooklyn: 718-946-5500 · Northeast Philadelphia: 215-676-2334

Use the form only for a non-urgent callback request. Do not submit private medical, insurance, financial or other sensitive information.


    For appointments and important matters, please call the appropriate W8MD office:


    Philadelphia:
    215-676-2334

    Brooklyn / New York City:
    718-946-5500


    Do not use this form for emergencies or urgent medical concerns.
    Call 911 or go to the nearest emergency department for an emergency.


    This form is only for non-urgent appointment and general service requests.
    Do not submit symptoms, diagnoses, medication details, insurance numbers,
    financial information, Social Security numbers, or other confidential
    information.









    Security verification

    Please answer the following question:






    Fields marked with an asterisk are required. Appointment availability,
    services and treatment eligibility vary. A medical evaluation is required
    before treatment or prescribing.

    Medical and research notice: Educational information only. Trial status and regulatory status can change. The first W8MD visit is in person. No drug, trial enrollment, prescription, coverage, availability or outcome is guaranteed. Call 911 for an emergency.

    Status reviewed September 4, 2026. Recheck FDA labeling and ClinicalTrials.gov before relying on this page.

    Start typing and press Enter to search

    Shopping Cart